The difference in prices for U.S. shale oil in West Texas and at Houston has widened in the last two months on dwindling ...
Occidental is teaming up with another major Houston-based energy company for a project near the Houston Ship Channel.
HOUSTON (AP) — HOUSTON (AP) — Plains All American Pipeline L.P. (PAA) on Friday reported third-quarter earnings of $220 million. On a per-share basis, the Houston-based company said it had profit of ...
This trend is only expected to begin reversing in 2028, when Yardi Matrix estimates that the United States will see 404,559 new multifamily units. And in 2029, Yardi Matrix predicts that 426,485 new ...
Plains All American Pipeline, L.P. (Nasdaq: PAA) and Plains GP Holdings (Nasdaq: PAGP) today reported third-quarter 2024 results. Third-Quarter Results Reported net income attributable to PAA of $220 ...
Shale pipeline operator EPIC Consolidated Operations is also exploring a significant expansion. CEO Brian Freed stated they ...
Plains Still Lacks of Pricing Power Due to Oversupply of Crude Oil Long-Haul Pipeline Infrastructure
Plains signed contracts for its Permian long-haul pipeline portfolio that extended the duration ... is less valuable in this environment where more barrels are moving to the Houston complex for export ...
U.S. midstream company MPLX reported a 12% rise in its third-quarter profit on Tuesday as it transported more volumes through its pipeline systems.
CALGARY, Alberta (AP) — CALGARY, Alberta (AP) — Pembina Pipeline Corp. (PBA) on Tuesday reported third-quarter profit of $280.8 million. The Calgary, Alberta-based company said it had profit of 44 ...
A controversial pipeline project is seeking regulatory approval to shorten ... PRGT, co-owned by the Nisga’a and Houston-based Western LNG, is currently seeking approval from the provincial regulator ...
2h
Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab, in a late-breaker poster presentation at the ...
BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback